Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429457 | 0.81 | ALDH1A1 (0.40) | POLBLMNAHPGDHSD17B10 | |
| SCHEMBL361093 | 0.80 | ESR2 (0.36) | POLBRECQLESR2CES2CES1 | |
| SCHEMBL20854261 | 0.79 | ALDH1A1 (0.39) | POLBLMNAHPGDHSD17B10 | |
| SCHEMBL18289517 | 0.78 | MEN1 (0.35) | POLBRECQLESR2 | |
| SCHEMBL259655 | 0.74 | EGFR (0.42) | POLBRECQLESR2CYP4F2CYP4A11 | |
| SCHEMBL2622530 | 0.74 | ALDH1A1 (0.47) | POLBRECQLESR2HIF1ALMNA | |
| Hydrochloric Acid SCHEMBL27763840 | 0.74 | CYP4F2 (0.40) | RECQLCES2CES1CYP4F2CYP4A11 | |
| SCHEMBL7662070 | 0.74 | NT5E (0.47) | POLBHIF1AHPGD | |
| SCHEMBL819786 | 0.74 | MYC (0.44) | — | |
| SCHEMBL20719962 | 0.73 | CA1 (0.39) | POLBRECQLESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023309-B1 | HIGH SURFACE DENSITY COVALENT IMMOBILIZATION OF OLIGONUCLEOTIDE MONOLAYERS | SENSORCHEM INTERNAT CORP (CA) | 2003-09-03 | — | — | EP | claimed |
| US-20240319424-A1 | PATTERNED COATABLE THIN-FILM POLARIZER BASED ON LYOTROPIC LIQUID CRYSTAL | LIGHT POLYMERS HOLDING (KY) | 2024-09-26 | — | — | US | disclosed |
| US-12072520-B2 | Linear polarizers and methods of forming a linear polarizer | LIGHT POLYMERS HOLDING (KY) | 2024-08-27 | — | — | US | disclosed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| US-20230145287-A1 | LINEAR POLARIZERS AND METHODS OF FORMING A LINEAR POLARIZER | LIGHT POLYMERS HOLDING (KY) | 2023-05-11 | — | — | US | disclosed |
| US-20230145287-A1 | LINEAR POLARIZERS AND METHODS OF FORMING A LINEAR POLARIZER | LIGHT POLYMERS HOLDING (KY) | 2023-05-11 | — | — | US | disclosed |
| US-20230145287-A1 | LINEAR POLARIZERS AND METHODS OF FORMING A LINEAR POLARIZER | LIGHT POLYMERS HOLDING (KY) | 2023-05-11 | — | — | US | disclosed |
| US-11370914-B2 | Methods of forming polymeric polarizers from lyotropic liquid crystals and polymeric polarizers formed thereby | LIGHT POLYMERS HOLDING (KY) | 2022-06-28 | — | — | US | disclosed |
| US-10765759-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | disclosed |
| US-20040126838-A1 | Follicle stimulating hormone: remodeling and glycoconjugation of FSH | NEOSE TECHNOLOGIES, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1023309-B1 | HIGH SURFACE DENSITY COVALENT IMMOBILIZATION OF OLIGONUCLEOTIDE MONOLAYERS | SENSORCHEM INTERNAT CORP (CA) | 2003-09-03 | — | — | EP | disclosed |
| US-6169194-B1 | COMPOUND USED AS COMPONENT OF NOVEL SILANIZATION PROCEDURE WHICH ALLOWS VERY HIGH DENSITY MONOLAYER OF EXPOSED THIOL GROUPS TO BE PLACED ON VARIETY OF HYDROXYLIC SURFACES IN REPRODUCIBLE MANNER | SENSORCHEM INTERNATIONAL CORPORATION (CA) | 2001-01-02 | — | — | US | disclosed |
| US-6159695-A | High surface density covalent immobilization of oligonucleotide monolayers | SENSORCHEM INTERNATIONAL CORPORATION (CA) | 2000-12-12 | — | — | US | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | POLB 3982/4885RECQL 4761/4885ESR2 2832/4885 |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | IFNG, IFNAR1, IRF3 | POLB 843/4885RECQL 3537/4885ESR2 2658/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | POLB 2938/4885RECQL 4180/4885ESR2 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.